Table 1.
FGFR inhibitors in urothelial carcinoma, currently under clinical trial or marked.
| Medication | Target | Population | Phase | Comedication | NCT |
|---|---|---|---|---|---|
| Erdafitinib | FGFR1–3 | FGFR2/3 mutation or fusion | Marked | n.a. | NCT02365597 |
| Ib/II | Cetrelimab | NCT03473743 | |||
| Pemigatinib | FGFR1–3 | FGF or FGFR alteration platinum ineligible, FGFR3 mutation or rearrangement | II | n.a. | NCT02872714 |
| Pembrolizumab | NCT04003610 | ||||
| Rogaratinib | FGFR1–4 | High FGFR1 or 3 expression cisplatin ineligible | II/III | n.a. | NCT03410693 |
| High FGFR1 or 3 expression | IB/II | Atezolizumab | NCT03473756 | ||
| Infigratinib | FGFR1–3 | Altered FGFR3 | III | n.a. | NCT04197986 |
| Futibatinib | FGFR1–4 | Any solid tumor and disease progression/At least one FGF/FGFR mutation | I/II | n.a. | NCT02052778 |
| Advanced/metastatic cancer with FGFR2 aberration | III | Gemcitabine/Cisplatin | NCT04093362 | ||
| Advanced/metastatic urothelial carcinoma with or without FGFR mutation | II | Pembrolizumab | NCT04601857 | ||
| Dovitinib | FGFR1–3 | Urothelial carcinoma both with mutant FGFR3 and wild-type FGFR3 | II | n.a. | NCT00790426 |
| Vofatamab | FGFR3 | Stage IV locally advanced/metastatic urothelial carcinoma, FGFR3 mutation | Ib/II | Docetaxel | NCT02401542 |
| II | Pembrolizumab | NCT03123055 | |||
| Derazantinib | FGFR1–4 | Locally advanced/metastatic solid tumor with FGFR aberration | I/II | n.a. | NCT01752920 |
FGF (fibroblast growth factor); FGFR (fibroblast growth factor receptor); n.a. (not applicable).